1 / 44

Bipolar Disorder: New Treatment Options

Bipolar Disorder: New Treatment Options. Michael A. Chan, MD Chair, Department of Psychiatry Mount Carmel. Bipolar Disorder. Significant Public Health Impact 0.5 – 1.7% lifetime prevalence 6.4% lifetime prevalence “bipolar spectrum”¹ Suicide rate ~ 12% Annual U.S. cost > $45.2 B²

hoyt-jarvis
Download Presentation

Bipolar Disorder: New Treatment Options

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Bipolar Disorder:New Treatment Options Michael A. Chan, MD Chair, Department of Psychiatry Mount Carmel

  2. Bipolar Disorder • Significant Public Health Impact • 0.5 – 1.7% lifetime prevalence • 6.4% lifetime prevalence “bipolar spectrum”¹ • Suicide rate ~ 12% • Annual U.S. cost > $45.2 B² • 6th leading cause of disability worldwide³ • Co-morbid substance abuse (ETOH) ~70% • 90% recurrence rate (median # episodes = 9) • 50% recurrence within one year of 1st episode ¹Judd LL, et al. J Affect Disord 2003 Jan;73(1-2):123-31 ²Kleinman L, et al. Pharmacoeconomics 2003;21(9):601-22 ³Woods SW. J Clin Psych 2000;61(suppl 13):38-41.

  3. Bipolar Disorder • Often misdiagnosed or undiagnosed: • 35-60% have depression first¹ • May have several depressive episodes prior to manic episode² • Many will not report mania/hypomania • May progress to psychosis • Lag between symptom onset and first treatment with mood stabilizer³ ¹Goodwin FK, Jamison KR. Manic-Depressive Illness 1990:56-73;NY: Oxford Univ Press ²Lish JD, et al. J Affect Disord. 1994;31:281-294. ³Goldberg JF, Ernst CL. J Clin Psych. 2002 Nov;63(11):985-91.

  4. Bipolar Disorder:Clues to Diagnosis • History of mania • Family history of bipolar disorder • Earlier age of onset¹ • Multiple episodes • Abrupt onset and termination of depressive episodes • Worsening with antidepressant treatment² ¹Lish JD, et al. J Affect Disord. 1994 Aug;31(4):281-94. ²Ghaemi SN, et al. J Clin Psychiatry. 2000;61:804-808.

  5. Bipolar Disorder:DSM-IV Criteria for Manic Episode • Abnormally and persistently elevated, expansive, or irritable mood > 1 week • 3* or more activation symptoms: • Distractibility, Increased risk-taking, Grandiosity, Fast/racing thoughts, Activity increased, Sleep decreased, Talkativeness (“DIG FAST”) • Marked social/occupational impairment • Not due to drugs or medical condition *Four, if primarily irritable

  6. Bipolar Disorder:DSM-IV Criteria for Depression • 5 or more of following present > 2 weeks: • depressed mood most of day, nearly every day • decreased interest or pleasure in activities most of day, nearly every day • increased/decreased appetite & weight • increased/decreased sleep • psychomotor agitation/retardation • decreased energy • guilt/worthlessness • poor concentration • recurrent thoughts of death/suicide • “SIG: E-CAPS”

  7. Bipolar Patients Are Symptomatic Almost Half Their Lives N=146 12.8-year follow-up Judd et al. Arch Gen Psychiatry 2002;59:530-537

  8. Bipolar II Patients Are Symptomatic Most Of Their Lives N=86 13.4-year follow-up Judd LL, et al. Arch Gen Psychiatry 2003;60:261-269.

  9. Bipolar Disorder:Subtypes • Mixed Mania • Simultaneous mania and depression • May be > 40% prevalence of episodes* • Rapid Cycling • > 4 episodes/year • Bipolar II • Hypomania (< 4 days duration) alternating with depression • Secondary Mania • e.g., drugs, tumor, CVA, lupus, endocrine, infectious, Huntington’s, Wilson’s *Akiskal HS, et al. J Affect Disord 2000 Sep;59 Suppl 1:S5-S30

  10. Treatment:APA Practice Guidelines 2002 • Acute mania/mixed mania: • 1st line: lithiumor valproate or antipsychotic* • 1st line severe: lithiumor valproate + antipsychotic* • Acute depression: • 1st line: lithiumor lamotrigine • 1st line severe: lithium + antidepressant • Maintenance • lithiumor valproate: • Alternatives: lamotrigine, carbamazepine, oxycarbazepine • Atypical antipsychotics “may be considered” *APA recommends atypical antipsychotics > typical antipsychotics

  11. Treatment:Mood Stabilizers Lithium* Depakote* (divalproex sodium) Lamictal* (lamotrigine) Tegretol (carbamazepine) Trileptal (oxcarbazepine) Neurontin (gabapentin) Topamax (topiramate) Gabitril (tiagibine) Keppra (levetiracetam) *FDA-approved

  12. Mood Stabilizers:Lithium • Advantages: • 50+ years worldwide experience (FDA-approved 1970) • effective in euphoric mania and hypomania • inexpensive • reduces suicide rate¹‚² • Disadvantages: • slow onset ~ 14 days • narrow therapeutic index • non-response in > 50% (usually bipolar subtypes) • frequent side effects (polyuria, tremor, GI symptoms) and non-compliance • discontinuation associated with high relapse rate³ ¹Baldessarini RJ, et al. J Clin Psychiatry. 2003;64 Suppl 5:44-52. ²Goodwin FK, et al. JAMA. 2003 Sep 17;290(11):1467-73. ³Cavanagh J, et al. Acta Psychiatr Scand. 2004 Feb;109(2):91-5.

  13. Mood Stabilizers:Lithium • Predictors of response to Lithium: • euphoric mania • good inter-episode functioning • family history of Bipolar Disorder (and of Lithium response¹) • mania/depression/euthymia sequence vs. depression/mania/euthymia² ¹Duffy A, et al. J Clin Psych. 2002 Dec;63(12):1171-8. ²Kleindienst N, Greil W. Neuropsychobiology. 2002;42 Suppl 1:2-10.

  14. Mood Stabilizers:Divalproex • Advantages: • extensive experience (FDA-approved for epilepsy 1983; for bipolar mania 1995) • rapid onset (1-4 days) • loading dose strategy¹ well-tolerated: • 20 mgs/kg • 77% moderate to marked response • effective in Bipolar subtypes • effective for psychotic symptoms² • plasma levels (50-125 mcg/ml) • less cognitive impairment than lithium³ ¹McElroy SL, Keck PE. Neuropsychobiol. 1993;27(3):146-9. ²McElroy SL, et al. J Clin Psych. 1996 Apr;57(4):142-6. ³Zajecka J, et al. J Clin Psych. 1996 Aug;57(8):356-9.

  15. Mood Stabilizers:Divalproex • Disadvantages: • sedation • transient hair loss • weight gain • tremor • GI upset • dose-related thrombocytopenia • rare hepatotoxicity, pancreatitis • possible Polycystic Ovarian Syndrome • plasma level monitoring

  16. Mood Stabilizers:Lamictal • FDA-approved for maintenancetreatmentof Bipolar I Disorder • Black box warning for serious rash (includes Stevens-Johnson Syndrome and toxic epidermal necrolysis) • Slow titration necessary • Interaction with other AEDs (especially valproic acid and carbamazepine)

  17. Lamictal:Efficacy in Bipolar Disorder • Placebo controlled 18-month trials of lamotrigine and lithium – pooled analysis • 8-16 week open label treatment with lamotrigine or lithium before randomization: • N = 191 for placebo • N = 280 for lamotrigine (100-400 mgs/d) • N = 167 for lithium (0.8-1.1 mEq/L) • 18-month maintenance treatment phase • Both lamotrigine and lithium superior toplacebo in preventing any mood episode Goodwin GM, et al;J Clin Psych 2004 Mar;65(3):432-441 Bowden CL, et al;Arch Gen Psych 2003 Apr;60(4):392-400 Calabrese JR, et al;J Clin Psych 2003 Sep;64(9):1013-1024

  18. Treatment:Atypical Antipsychotics • Clozaril (clozapine) • Risperdal* (risperidone) • Zyprexa* (olanzapine) • Seroquel* (quetiapine) • Geodon* (ziprasidone) • Abilify* (aripiprazole) *FDA-approved

  19. Atypical Antipsychotics • Comparable efficacy on positive symptom • Better efficacy for improving cognitive and affective (“negative”) symptoms • Less risk of extrapyramidal symptoms ______________________________________ • “Brightening” effects related to receptor actions that differ from one agent to another • Appropriate dosing is key for optimal benefits with any atypical

  20. Antipsychotic Receptor Binding Profiles Haloperidol Olanzapine Clozapine Quetiapine Risperidone Ziprasidone Receptor: A1, 2 = a1, a2 adrenergic D1,2 = dopamine H1 = histamine 5HT1A, 2A = serotonin M = muscarinic Goldstein 1999

  21. Atypical Antipsychotics • High 5HT2:DA blockade (aripiprazole: unique mechanism) • 5HT-2a antagonism: • Mesolimbic: does not reverse antipsychotic action at D2 receptors • Nigrostriatal: reverses enough D2 blockade to EPS • Mesocortical: DA enough to improve cognition

  22. Atypical Antipsychotics • Receptor actions that improve mood and cognition: • 5HT2a antagonism(CLZ/RIS/OLZ/QTP/ZIP/ARI) • 5HT2c antagonism (RIS/OLZ/ZIP) • 5HT1a agonism (CLZ/QTP/ZIP/ARI) • 5HT/NE reuptake blockade (ZIP)

  23. Atypical Antipsychotics Proper dosing:

  24. Evaluation of Mania • Young Mania Rating Scale items*: • Elevated mood • Increased motor activity • Sexual interest • Sleep • Irritability • Speech • Language • Content • Disruptive/aggressive behavior • Appearance • Insight *Possible Score = 0-60

  25. Antipsychotics:Olanzapine • FDA-approved for acute mania (2000) and bipolar maintenance (2004) • First-line treatment for mania per APA 2002Practice Guidelines (along with lithium & divalproex) • Superior to placebo¹ • Equivalent to lithium² • Superior efficacy (vs. placebo) as add-on to lithium or valproate ³ • Superior to divalproex4 1. Tohen M, et al. Am J Psych. 1999 May;156(5):702-9. 2. Berk M, et al. Int Clin Psychopharmacol. 1999 Nov;14(6):339-43. 3. Tohen M, et al. Arch Gen Psych. 2002 Jan;59(1):62-9. 4. Tohen M, et al. Am J Psych. 2003 Jul;160(7):1263-71.

  26. Antipsychotics:Risperidone • FDA-approved for acute mania (2003) • Superior to placebo (equivalent tohaloperidol) as add-on to mood stabilizer (lithium or divalproex)¹ • Equivalent to lithium or haloperidol monotherapy² ¹Sachs, et al. Am J Psych 2002 Jul;159(7):1146-54 ²Segal J, et al. Clin Neuropharm 1998 May-Jun;21(3):176-80

  27. Antipsychotics:Quetiapine • FDA-approved for acute mania up to 12 weeks (2004) • 2 monotherapy and 2 adjunct therapy studies completed* • Superior efficacy on YMRS, PANSS, CGI (including Response and Remission rates on YMRS) for 3 of 4 studies *Data on file, AstraZeneca Pharmaceuticals LP, Wilmington, DE Presented at 16th Annual U.S. Psychiatric & Mental Health Congress. Nov 6-9, 2003. Orlando, FL

  28. Quetiapine:Safety SummaryMonotherapy/Adjunct Therapy • No clinically significant changes observed on ECG parameters (including QTc) • No clinically significant changes in glucose levels (random test) from baseline to endpoint • No other laboratory abnormalities occurred • No clinically significant change observed in blood pressure (including orthostatic) • No difference from placebo in EPS or prolactin levels • No difference from placebo in withdrawal due to adverse events

  29. Antipsychotics:Ziprasidone • FDA-approved for mania August 2004 • 3-week, double-blind, randomized trial (DSM-IV mania/mixed mania) • N = 210 • Ziprasidone 40-80 mgs B.I.D. vs. placebo • Outcome: SADS (MRS), PANSS, CGI-I, CGI-S, GAF • Ziprasidone superior from day 2 on all primary and most secondary efficacy measures Keck PE, et al. Am J Psych. 2003 Apr; 160(4):741-8.

  30. Antipsychotics:Aripiprazole • FDA-approved for mania October 2004 • 3-week, multi-center, double-blind, randomized trial (acute mania/mixed mania) • N=262 • aripiprazole 30 mgs vs. placebo • Outcome: YMRS change from baseline and response rate ( > 50%) • aripiprazole superior from day 4: • YMRS (-8.2 vs. –3.4) • YMRS response (40% vs. 19%) • Similar discontinuation rate, weight, prolactin, QTc Keck PE, et al. Am J Psych. 2003 Sep; 160(9):1651-8.

  31. Atypical Antipsychotics:Metabolic Abnormalities (+) = increase; (–) = no effect; D = discrepant results Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care. 2004 Feb. 27(2):596-601.

  32. Atypical Antipsychotics:Case Reports Summary* *Data from MedWatch and Koller et al. Am J Med. 2001;111:716-23/ Koller et al. Pharmaotherapy. 2002;22:841-52. °J Clin Psychiatry 2004;65:857-863 Literature reports through July 2003 and post-marketing surveillance date through August 2002

  33. Comparative Side Effect Profile of Atypical Neuroleptics

  34. Benefits of Lower EPS • “Negative” symptom benefits • Cognitive benefits • Decreased dysphoria • Improved compliance • Lower risk for tardive dyskinesia Tandon R, Jibson MD. Annals Clin Psychiatry 2002;14(2):123-9.

  35. Prolactin Elevation* • Loss of libido • Anorgasmia/Ejaculation difficulty • Amenorrhea • Gynecomastia • Galactorrhea • Osteoporosis *DA blockade in tubero-infundibular tract

  36. Treatment:Antidepressants • Appropriate use and effectiveness is controversial • Antidepressant-induced mania in 20-40% with all antidepressant classes (TCAs > others)¹‚² • Increased risk of switching³: • Previous antidepressant-induced mania • Bipolar family history • Exposure to multiple antidepressant trials ¹Stoll AL, et al. Am J Psych 1994 Nov;151(1):1642-45 ²Calabrese JR, et al. Eur Neuropsychopharm 1999 Aug;9 Suppl 4:S109-12 ³Goldberg JF, et al. Bipolar Disord 2003 Dec;5(6):407-20

  37. Treatment:Antidepressants • Conflicting evidence for efficacy against depressive relapse: • Protective?: • Altshuler L, et al¹ (retrospective, 39 pts, 1 year): • 35% relapse rate with antidepressant continuation • 68% relapse rate with antidepressant discontinuation • Altshuler L, et al² (prospective, 84 pts, 1 year): • 36% relapse rate with antidepressant continuation • 70% relapse rate with antidepressant discontinuation ¹Altshuler L, et al. J Clin Psychiatry. 2001;62:612-16. ²Altshuler L, et al. Am J Psychiatry. 2003;160:1252-62.

  38. Treatment:Antidepressants • No benefit?: • Frankle WG, et al¹ (retrospective, 50 pts, 30 weeks): • No difference in length of depressive episode regardless of antidepressant status • Ghaemi S, et al² (open, randomized 33 pts, 1 year): • Relapse rate 50% within 20 weeks regardless of antidepressant status ¹Frankle WG, et al. Psychol Med. 2002 Nov;32:1417-23. ²Ghaemi S, et al. San Juan, PR: American College of Neuropsychopharmacology annual meeting, 2003.

  39. Treatment:Antidepressants • Antidepressants can be safe and effective* • Review of 12 randomized, controlled trials in Bipolar Depression (1,088 patients): • Antidepressants more effective than placebo • Switch rate 3.8% for antidepressants and 4.7% for placebo • Tricyclics had 10% switch rate vs. 3.2% for all other antidepressants *Gijsman HJ, et al. Am J Psychiatry 2004; 161:1537-1547.

  40. Treatment:Antidepressants • Recommendations for Bipolar depression*: • Augment mood stabilizer with antidepressant, unless: • “ultra-rapid” cycler (>4 episodes/week) • History of antidepressant-induced cycle acceleration • History of multiple episodes antidepressant-induced mania despite mood stabilizer treatment • Continue maintenance antidepressant if stable for 2 months *Post RM. Current Psychiatry. 2004 July. 3(7):40-49.

  41. Treatment • Electroconvulsive treatment¹‚²: • superior to pharmacotherapy • bilateral ECT superior to unilateral ECT • psychotic depression predicts better response • effective in depressed and manic phases • > 300 case reports of ECT during pregnancy • Phototherapy (bright light treatment) • Benefit as monotherapy³ or augmentation4 • especially if seasonal component • Sleep deprivation5 • improvement in 40-60% (may last weeks) • some risk of hypo-mania ¹UK ECT Review Group. Lancet. 2003 Mar 8;361(9360):799-808; ²Kho KH, et al. J ECT. 2003 Sep;19(3):139-47; ³Levitt AJ, et al. J Affect Disord. 2002 Sep;71(1-3):243-8; 4Loving RT, et al. Depress Anxiety. 2002;16(1):1-3; 5Giedke H, Schwarzler F. Sleep Med Rev. 2002 Oct;6(5):361-77.

  42. Treatment • Psychotherapy issues: • acceptance of illness • effect of illness on relationships • effect on employment • enhance compliance (>50% non-compliance: M>F, white>non-white, combination therapy>monotherapy, substance abusers)* • identify precipitants to mood episodes • manage/reduce stress *Keck PE, et al. Psychopharm Bull 1997;33(1):87-91

  43. Summary • Bipolar disorder: • Significant public health impact • Highly recurrent • Must look to find • Usually presents in depressed phase • Subtypes exist and are less lithium-responsive • First-line treatment: • Mood stabilizers • Atypical antipsychotics

  44. Bipolar Disorder:New Treatment Options Michael A. Chan, MD Chair, Department of Psychiatry Mount Carmel

More Related